BioNTech’s $16.7 Billion Question: Can Cancer Drugs Fill the COVID Void?

BioNTech faces a Q1 loss per share of $2.54, but analysts remain bullish on its oncology pipeline, led by pumitamig. Insider sales and founder exit add caution.

The numbers tell a stark story. BioNTech is sitting on a liquidity reserve of roughly €16.7 billion, yet analysts expect the company to post a loss of about $2.54 per share when it reports first-quarter results on May 5. The COVID revenue decline is old news. What investors really want to know is whether the oncology pipeline can deliver before the cash pile starts shrinking.

The stock closed Wednesday at €85.40, up nearly 11% over the past month but still around 15% below its 52-week high. Year-to-date, shares have managed a modest gain of roughly 5% — not a breakout, but hardly a collapse.

Wall Street Stays Bullish Despite the Red Ink

Thirteen analysts cover BioNTech, and their consensus rating is “Buy” with an average price target of about $133. HC Wainwright reaffirmed its “Buy” recommendation in late April with a $130 target. Morgan Stanley raised its target to $126 and kept an “Overweight” rating. Goldman Sachs and Berenberg also remain in the buy camp.

The range of estimates is unusually wide — from below $77 to well above that level — reflecting deep disagreement about the pipeline’s trajectory and the risks surrounding the upcoming leadership transition.

Pumitamig: The Billion-Dollar Bet

The valuation argument increasingly hinges on pumitamig (BNT327). Bristol Myers Squibb secured rights to this bispecific antibody in June 2025 for up to $11 billion. Nine Phase 3 trials are now underway for the drug, which targets both PD-(L)1 and VEGF pathways — currently the best-funded concept in oncology.

Competition is fierce. Akeso, Pfizer, and AbbVie are all pushing similar approaches into the same market. BioNTech plans to launch six new Phase 3 studies in 2026 and expects seven late-stage data readouts. But the company isn’t banking on any oncology revenue this year. Full-year revenue is forecast between €2 billion and €2.3 billion, while R&D spending could reach €2.5 billion.

Insider Sale Adds a Note of Caution

Just days before the earnings release, CFO Sierk Poetting sold 50,000 BioNTech shares in late April, netting roughly $5.5 million. After the transaction, he still holds nearly 400,000 shares indirectly. Insider sales are routine, but the timing — right ahead of a potentially ugly quarterly report — keeps the market on edge.

Founders Exit Without a Final Contract

Ugur Sahin and Özlem Türeci are leaving BioNTech by the end of 2026. The supervisory board is searching for successors, but a binding agreement on the technology transfer to their new company has yet to be finalized. That deal is supposed to be in place by mid-2026. Until it is, the financial terms remain unknown.

Two Continents, Two Strategies

While the market focuses on quarterly losses and pipeline timelines, BioNTech is quietly expanding its physical footprint. The cities of Mainz and Heidelberg have signed a letter of intent to develop the Neckar-Rhein-Main region into an international biotech hub, with BioNTech supporting the initiative at its home base.

Simultaneously, the company is pushing ahead with production in Rwanda. The Kigali facility uses modular units and aims to establish a complete local manufacturing chain for mRNA vaccines. It’s a long-term bet on African self-sufficiency that has little bearing on next week’s earnings but signals where management sees future demand.

The May 5 earnings call will be the first real test of whether BioNTech can bridge the gap between its COVID past and its oncology future — and whether the €16.7 billion war chest buys enough time to get there.